ReviewHeart (British Cardiac Society)2007
Renin: friend or foe?
Review in Heart (British Cardiac Society), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Comparative effects of angiotensin II stimulating and inhibiting antihypertensives on dementia risk: a systematic review and meta-analysis.GeroScience · 2025Pooled it
- Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels.Journal of human hypertension · 2025Pooled it
- The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.Journal of human hypertension · 2019Pooled it
- Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis.Heart failure reviews · 2018Pooled it
- Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial.Neurology · 2021Trial
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet (London, England) · 2015Trial
- Trial
- Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin-II Formation: Findings From the 45 and Up Study.International journal of geriatric psychiatry · 2026Article
- Decoding cardiorenal crosstalk: Intercellular communication mechanisms and therapeutic insights in cardiorenal syndrome.iScience · 2026Review
- Angiotensin II-stimulating versus inhibiting antihypertensives and risk of dementia: a nested case-control study using Australian general practice data.Scientific reports · 2026Article
- Comparative analysis of pathways induced by TMAO and TNF-α in human microvascular endothelial cells.Scientific reports · 2026Article
- A Cross-Sectional Study of Sex-Specific Associations of Renin and Electrolytes on the Development of Hypertension.Journal of clinical medicine · 2026Article
- Novel pharmacological approaches to lowering blood pressure and managing hypertension.Nature reviews. Cardiology · 2025Review
- Empagliflozin and fluid balance: results from the SiRENA project.Clinical kidney journal · 2025Article
- The Renin-Angiotensin System and Cardiovascular-Kidney-Metabolic Syndrome: Focus on Early-Life Programming.International journal of molecular sciences · 2024Review
- Response surface analyses of antihypertensive effects of angiotensin receptor blockers and amlodipine or hydrochlorothiazide combination therapy in patients with essential hypertension.Translational and clinical pharmacology · 2023Article
- A pilot study to evaluate the erythrocyte glycocalyx sensitivity to sodium as a marker for cellular salt sensitivity in hypertension.Journal of human hypertension · 2023Article
- ER ribosomal-binding protein 1 regulates blood pressure and potassium homeostasis by modulating intracellular renin trafficking.Journal of biomedical science · 2023Article
- Time to eRAASe chronic inflammation: current advances and future perspectives on renin-angiotensin-aldosterone-system and chronic intestinal inflammation in dogs and humans.Frontiers in veterinary science · 2023Article
- Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long-term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate-limiting step (beta blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.